Prenatal CMA concurrent with GenomeDx™ Prenatal

Prenatal Whole Genome Chromosomal Microarray (Prenatal CMA) with concurrent GenomeDx™ Prenatal, trio. Separate result reports will be issued for the prenatal CMA analysis and genome sequencing analysis.

Test Overview

Clinical Utility

  • Testing of prenatal samples, both ongoing and deceased fetuses
  • Identification of underlying molecular diagnosis
  • Recurrence risk assessment

Test Details

Conditions

  • Fetus with ultrasound anomalies

Lab Method

  • Next-Gen Sequencing
  • Whole Genome Chromosomal Microarray

Ordering Information

Important Information

Prenatal Whole Genome Chromosomal Microarray (Prenatal CMA) with concurrent GenomeDx™ Prenatal, trio. Separate result reports will be issued for the prenatal CMA analysis and genome sequencing analysis.

Trio — Test Code: _GD1008a_460 · CPT Codes*: Prenatal CMA 81229x1; GenomeDx™ Prenatal 81425x1, 81426x2
Duo — Test Code: _GD1008e_460 · CPT Codes*: Prenatal CMA 81229x1; GenomeDx™ Prenatal 81425x1, 81426x1
Proband — Test Code: _GD1008b_460 · CPT Codes*: Prenatal CMA 81229x1; GenomeDx™ Prenatal 81425x1
ABN Required: No
Turnaround Time**: 2 weeks
Preferred Specimen: 30 mL Amniotic Fluid | 2 T25 flasks of cultured amniocytes | 2 T25 flasks of cultured chorionic villi | 30 mg CVS | 5 µg DNA Concentration | POC or other fetal tissue
Minimum Specimen:

20 mL Amniotic Fluid | 20 mg CVS
Samples below the minimum amounts may be accepted, please contact [email protected] in advance to review.

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**2 weeks. Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control. Note that if the submitted specimen requires cell culturing, this will delay the start of testing.

Resources

Test Documents

Billing

Targeted Variant Testing

FAQs